Skip to main content
Clinical Trials/NCT04497610
NCT04497610
Withdrawn
Not Applicable

SARS-CoV-2 (COVID-19) Detection Using the Breath Analizer TeraSystem

Instituto Costarricense de Investigaciones Clínicas ICIC1 site in 1 countryNovember 2022
ConditionsCOVID19

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
COVID19
Sponsor
Instituto Costarricense de Investigaciones Clínicas ICIC
Locations
1
Primary Endpoint
Presence of disease
Status
Withdrawn
Last Updated
3 years ago

Overview

Brief Summary

The purpose of the study is to verify the sensibility and accuracy of a rapid detection test for SARS-CoV-2 in breath samples analyzed by the breath detector analyzer TeraSystem, comparing with PCR tests.

Detailed Description

BioSafety Technologies has developed a rapid detection test to clear people of COVID-19. A person can undergo an easy non-invasive test, to determine if they are: COVID-19 Clear (Negative) or Infected (Positive). The user-friendly process does not involve medically trained personnel. The study will compare TeraSystem test results against PCR test results. Persons participating will be persons having a PCR test as part of the Health System and consenting to participate.

Registry
clinicaltrials.gov
Start Date
November 2022
End Date
November 2022
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Instituto Costarricense de Investigaciones Clínicas ICIC
Responsible Party
Principal Investigator
Principal Investigator

Dr. Guillermo Rodríguez Gómez

Founder

Instituto Costarricense de Investigaciones Clínicas ICIC

Eligibility Criteria

Inclusion Criteria

  • Older than 7 years odf age Able to provide informed consent Able to take the breath test

Exclusion Criteria

  • Younger than 7 years of age Unable to provide informed consent Unable to take the breath test

Outcomes

Primary Outcomes

Presence of disease

Time Frame: 1 minute

Established diagnosis

Study Sites (1)

Loading locations...

Similar Trials